StoneX Group Inc. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 39.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,047 shares of the company’s stock after selling 2,588 shares during the period. StoneX Group Inc.’s holdings in Eli Lilly and Company were worth $4,683,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Torren Management LLC lifted its stake in shares of Eli Lilly and Company by 357.1% in the 3rd quarter. Torren Management LLC now owns 32 shares of the company’s stock valued at $37,000 after acquiring an additional 25 shares during the last quarter. Marshall & Sterling Wealth Advisors Inc. boosted its holdings in Eli Lilly and Company by 60.0% during the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after acquiring an additional 15 shares during the period. Foresight Capital Management Advisors Inc. purchased a new stake in Eli Lilly and Company during the 3rd quarter valued at about $49,000. AlphaCentric Advisors LLC purchased a new stake in Eli Lilly and Company during the 1st quarter valued at about $42,000. Finally, Caitlin John LLC bought a new position in Eli Lilly and Company during the 2nd quarter worth approximately $64,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.
Eli Lilly and Company Stock Performance
Eli Lilly and Company stock opened at $1,372.15 on Friday. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. The firm has a 50-day moving average of $1,215.24 and a 200-day moving average of $1,101.16. The firm has a market cap of $1.29 trillion, a P/E ratio of 44.54, a P/E/G ratio of 1.69 and a beta of 0.40. Eli Lilly and Company has a 1-year low of $850.51 and a 1-year high of $1,453.00.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. During the same period last year, the firm earned $7.02 earnings per share. Eli Lilly and Company’s quarterly revenue was up 38.6% on a year-over-year basis. Sell-side analysts expect that Eli Lilly and Company will post 35.70 EPS for the current year.
Eli Lilly and Company Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is 22.46%.
Key Headlines Impacting Eli Lilly and Company
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Lilly and Hims & Hers agreed to offer FDA-approved Zepbound and Foundayo through Hims & Hers’ telehealth platform. Eligible patients with a prescription can access Lilly’s self-pay prices—reportedly starting at $149—without leaving the platform. The deal could widen patient access and Lilly’s reach in the competitive obesity-treatment market. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
- Positive Sentiment: New Phase 3 results for investigational retatrutide showed substantial reductions in weight and knee pain among adults with obesity and knee osteoarthritis. Lilly also reported positive Phase 3b results for combining Taltz and Zepbound in people with psoriatic arthritis and obesity, supporting the potential of its medicines in additional patient groups. Lilly to showcase new retatrutide, Taltz and Zepbound data
- Negative Sentiment: Price competition across the GLP-1 market remains a risk to Lilly’s growth and drug margins, as branded treatments compete with lower-priced options and providers seek self-pay patients. Eli Lilly’s GLP-1 franchise faces growing price competition
Analyst Upgrades and Downgrades
A number of equities analysts have commented on LLY shares. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $1,413.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. Scotiabank increased their price objective on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a “sector outperform” rating in a research note on Friday, October 30th. Berenberg Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 target price on the stock in a report on Tuesday, September 15th. Wall Street Zen upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $1,650.00 target price on shares of Eli Lilly and Company in a research note on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,404.14.
Read Our Latest Stock Report on LLY
Insiders Place Their Bets
In other news, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the transaction, the executive vice president owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 13,500 shares of company stock worth $17,020,770. 0.14% of the stock is currently owned by company insiders.
About Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.
The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
